Flescher E - Search Results

1

Targeting anthracycline-resistant tumor cells with synthetic aloe-emodin glycosides.

Breiner-Goldstein E, Evron Z, Frenkel M, Cohen K, Meiron KN, Peer D, Roichman Y, Flescher E, Fridman M. Breiner-Goldstein E, et al. Among authors: flescher e. ACS Med Chem Lett. 2011 May 12;2(7):528-31. doi: 10.1021/ml2001104. eCollection 2011 Jul 14. ACS Med Chem Lett. 2011. PMID: 24900344 Free PMC article.

2

Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2.

Cohen S, Bruchim I, Graiver D, Evron Z, Oron-Karni V, Pasmanik-Chor M, Eitan R, Bernheim J, Levavi H, Fishman A, Flescher E. Cohen S, et al. Among authors: flescher e. J Mol Med (Berl). 2013 Mar;91(3):357-68. doi: 10.1007/s00109-012-0946-4. Epub 2012 Sep 28. J Mol Med (Berl). 2013. PMID: 23052480

3

Methyl jasmonate induces cell death with mixed characteristics of apoptosis and necrosis in cervical cancer cells.

Kniazhanski T, Jackman A, Heyfets A, Gonen P, Flescher E, Sherman L. Kniazhanski T, et al. Among authors: flescher e. Cancer Lett. 2008 Nov 18;271(1):34-46. doi: 10.1016/j.canlet.2008.05.031. Epub 2008 Jul 2. Cancer Lett. 2008. PMID: 18599197

4

Jasmonates in cancer therapy.

Flescher E. Flescher E. Cancer Lett. 2007 Jan 8;245(1-2):1-10. doi: 10.1016/j.canlet.2006.03.001. Epub 2006 Apr 4. Cancer Lett. 2007. PMID: 16600475 Review.

5

Methyl jasmonate reduces the survival of cervical cancer cells and downregulates HPV E6 and E7, and survivin.

Milrot E, Jackman A, Kniazhanski T, Gonen P, Flescher E, Sherman L. Milrot E, et al. Among authors: flescher e. Cancer Lett. 2012 Jun 1;319(1):31-8. doi: 10.1016/j.canlet.2011.12.028. Epub 2011 Dec 23. Cancer Lett. 2012. PMID: 22198483

6

Combined chemotherapy or biotherapy with jasmonates: targeting energy metabolism for cancer treatment.

Elia U, Flescher E. Elia U, et al. Among authors: flescher e. Curr Pharm Biotechnol. 2013;14(3):331-41. doi: 10.2174/1389201011314030008. Curr Pharm Biotechnol. 2013. PMID: 22201595 Review.

7

Effects of natural and novel synthetic jasmonates in experimental metastatic melanoma.

Reischer D, Heyfets A, Shimony S, Nordenberg J, Kashman Y, Flescher E. Reischer D, et al. Among authors: flescher e. Br J Pharmacol. 2007 Mar;150(6):738-49. doi: 10.1038/sj.bjp.0707146. Epub 2007 Feb 12. Br J Pharmacol. 2007. PMID: 17293888 Free PMC article.

8

Methyl jasmonate down-regulates survivin expression and sensitizes colon carcinoma cells towards TRAIL-induced cytotoxicity.

Raviv Z, Zilberberg A, Cohen S, Reischer-Pelech D, Horrix C, Berger MR, Rosin-Arbesfeld R, Flescher E. Raviv Z, et al. Among authors: flescher e. Br J Pharmacol. 2011 Nov;164(5):1433-44. doi: 10.1111/j.1476-5381.2011.01419.x. Br J Pharmacol. 2011. PMID: 21486277 Free PMC article.

9

Cooperative cytotoxicity of methyl jasmonate with anti-cancer drugs and 2-deoxy-D-glucose.

Heyfets A, Flescher E. Heyfets A, et al. Among authors: flescher e. Cancer Lett. 2007 Jun 8;250(2):300-10. doi: 10.1016/j.canlet.2006.10.013. Epub 2006 Nov 27. Cancer Lett. 2007. PMID: 17125916

10

IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer.

Bruchim I, Sarfstein R, Reiss A, Flescher E, Werner H. Bruchim I, et al. Among authors: flescher e. Cancer Lett. 2014 Oct 1;352(2):214-9. doi: 10.1016/j.canlet.2014.06.013. Epub 2014 Jul 2. Cancer Lett. 2014. PMID: 24997432

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

71 results

Search Page